Compare CASS & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | SGP |
|---|---|---|
| Founded | 1906 | 2019 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.9M | 650.9M |
| IPO Year | 1996 | N/A |
| Metric | CASS | SGP |
|---|---|---|
| Price | $52.04 | $22.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $45.00 | $45.00 |
| AVG Volume (30 Days) | 87.1K | ★ 155.2K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 87.77 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $190,750,000.00 | N/A |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $77.18 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $36.07 | $17.06 |
| 52 Week High | $53.19 | $30.56 |
| Indicator | CASS | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 64.00 | 61.57 |
| Support Level | $45.19 | $20.95 |
| Resistance Level | $52.82 | $22.80 |
| Average True Range (ATR) | 1.36 | 1.74 |
| MACD | -0.01 | 0.31 |
| Stochastic Oscillator | 74.81 | 93.20 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.